New therapeutic strategies in T2D such as glucagon-like peptide-1 (GLP1) receptor agonists were reported to counteract some alterations of circulating lipidome in T2D, including sphingolipids [60, 61], and to reduce the risk of atherosclerotic cardiovascular risk in T2D [62]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.